Antithrombotic therapy in the secondary prevention of myocardial infarction

Area of Science:

• Cardiology
• Thrombosis Research
• Pharmacology

Background:

• Myocardial infarction is frequently caused by coronary artery occlusion due to thrombus formation, often linked to ruptured atherosclerotic plaques.
• Thrombi comprise platelets and fibrin, suggesting dual antiplatelet and anticoagulant therapy could prevent recurrent thrombotic events.

Purpose of the Study:

• To review clinical trial evidence on the efficacy of antiplatelet and anticoagulant therapies in preventing secondary thrombotic vascular events post-myocardial infarction.
• To compare the effectiveness and practical considerations of aspirin versus oral anticoagulants, and to explore the potential of combination therapy.

Main Methods:

• Systematic review and analysis of existing clinical trials investigating antiplatelet (aspirin) and anticoagulant therapies.
• Examination of data regarding vascular mortality, total vascular events, and patient compliance.

Main Results:

• Aspirin reduces vascular mortality by approximately 12% and vascular events by 25%.
• Oral anticoagulants decrease total mortality by up to 20% and vascular events by about 40%, though with wider confidence intervals due to fewer large-scale trials.
• The EPSIM trial indicated equal efficacy between aspirin and oral anticoagulants, with superior patient compliance for aspirin.

Conclusions:

• Both aspirin and oral anticoagulants are beneficial in managing post-myocardial infarction patients.
• Aspirin is more widely used due to practical advantages in administration and control.
• Combined antiplatelet and anticoagulant therapy shows promise but requires further large-scale trials due to increased hemorrhage risk.